ArticleAdvances in therapy2023

Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Xinhua Zou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.